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Current measures of anticancer drug efficacy reflect bulk cell killing and are poorly suited to detect
activity against cancer stem cells (CSCs), which sustain tumor growth. The CSC paradigm necessi-
tates a reexamination of methodologies used to evaluate clinical efficacy of anticancer therapies, as
well as strategies employed during preclinical drug development.Introduction
Over the past decade, oncology drugs have been more
likely to progress to late phases of clinical testing compared
to other drug classes, but their chances of achieving mar-
keting approval upon phase III testing are, in contrast,
much lower (DiMasi and Grabowski, 2007). Agents may
fail phase III testing for any number of reasons, the most
common being excessive or unexpected toxicity and failure
to show improvements in survival or ‘‘time to tumor pro-
gression.’’ The high failure rate of oncology drugs in late
stages of clinical development suggests that the surrogate
endpoints currently used in phase I/II trials, which are usu-
ally based on objective demonstration of tumor response,
are not good predictors of long-term outcomes. The biolog-
ical basis for this discrepancy is being linked increasingly to
the recent evidence that the growth of many typesof human
cancer is sustained by cancer stem cells (CSCs), which are
distinct from bulk tumor cells that lack the ability to initiate
tumor growth (Jordan et al., 2006). CSCs are characterized
by the property of self-renewal (i.e., the ability to produce
more CSCs) and the capacity to generate all of the varied
cell types that make up the tumor. Current methods to as-
sess clinical efficacy, which are tailored to measure bulk tu-
mor cell killing, are poorly suited to gauge how well CSCs
areeliminated. Indeed, the high frequencyof relapse follow-
ing conventional cytotoxic chemotherapy suggests that
CSCs survive standard treatments, possibly related to
properties they share with normal stem cells, such as quies-
cence or expression of drug transporters (Guan et al., 2003;
Dean et al., 2005; Jordan et al., 2006; Bao et al., 2006). In
order to fill the clear need for new therapies that target these
cancer-sustaining cells, there must be a critical reexamina-
tion of current approaches for clinical evaluation of drug ef-
ficacy and, in parallel, for screening and preclinical testing
of novel anticanceragents. Improvedmethods for both pre-
clinical and clinical evaluation of anti-CSC efficacy may
facilitate prioritization of drug development by avoiding the
premature discard of active agents, and more efficiently
identifying ineffective drugs to be discontinued.Clinical Trial Design to Assess Anti-CSC Activity
For cancer therapeutics, the commonly accepted yard-
stick of clinical benefit has been demonstration of overall
survival benefit. Proper assessment of this endpoint is
generally only feasible in a phase III trial with accrual of
large numbers of patients and long-term follow-up. During
drug development, phase II trials are designed to deter-
mine rapidly whether a drug has sufficient activity to war-
rant further investigation in a costly, large-scale, random-
ized clinical trial and thus employ surrogate endpoints that
are assumed to correlate with improvements in patient
outcome. Historically, the design of phase II trials of cyto-
toxic anticancer agents has been based on the prediction
that such agents will shrink tumors and has used an objec-
tive decrease in tumor size to define clinical response. The
advantage of this approach is that the primary endpoint is
measurable over weeks to months, allowing efficient deci-
sion-making with respect to whether or not to proceed to
the next phase of clinical testing. However, for many can-
cers tumor response is not a good predictor of increased
survival. For example, patients with follicular lymphoma
treated with conventional cytotoxic chemotherapy have
high rates of complete remission but do not exhibit
improved survival compared to patients in whom treat-
ment is deferred until symptoms develop (a watchful wait-
ing approach) (Ardeshna et al., 2003). Similarly, treatment
of multiple myeloma patients with various cytotoxic drugs
gives no survival difference between patients who do or
do not exhibit a clinical response (Durie et al., 2004).
Numerous examples can also be cited in solid tumors
(Huff et al., 2006). A plausible explanation for the lack of
correlation between objective tumor response rates and
overall survival is that conventional cytotoxic therapies do
not kill the root of the cancer: the CSCs. Residual CSCs
that are not eradicated may reinitiate tumor growth, lead-
ing eventually to clinical relapse (Figure 1A).
In contrast to cytotoxic drugs, which target the bulk
proliferating cells and therefore can effect rapid tumor
shrinkage, agents that selectively eliminate the CSCsCell Stem Cell 1, November 2007 ª2007 Elsevier Inc. 497
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Conventional cytotoxic therapies reduce tumor bulk but do not eradicate cancer stem cells (CSCs), leading to regrowth of the tumor and relapse after
treatment (A). Agents that selectively eliminate CSCs will not induce rapid tumor shrinkage, but the remaining bulk cells do not have the ability to
sustain tumor growth and the tumor eventually degenerates (B). The most effective anticancer strategies will involve combination regimens that
both reduce tumor bulk and kill CSCs (C).within a tumor may bring about little or no immediate re-
duction in tumor size (Figure 1B); in fact, the downstream
progeny of CSCs may continue to expand, at least initially.
However, tumor growth is not sustainable without CSCs to
replenish the bulk population, and the tumor will eventu-
ally degenerate as bulk cells are depleted. In this context,
there is a significant risk that agents that selectively target
CSCs will be overlooked if assessed simply on the basis
of early objective tumor response. Even for therapeutic
approaches (whether single, sequential, or combination)
that kill both bulk tumor cells and CSCs (Figure 1C), the
best measure of whether the root of the cancer has been
eliminated lies in whether or not the tumor grows back.
Thus, in clinical testing, progression-free survival (PFS)—
defined as the probability that a patient remains alive with-
out disease progression—may be a more relevant end-
point for assessing the effectiveness of CSC killing than
tumor response. For example, treatment of xenograft
brain tumors in mice with the antiangiogenesis agent Bev-
acizumab, an antibody that neutralizes vascular endothe-
lial growth factor, inhibits tumor growth and depletes the
primitive CSC-containing CD133+ cell population by tar-
geting their vascular niche, but does not directly affect
bulk tumor cell proliferation or apoptosis (Calabrese et al.,
2007). Consistent with this agent’s lack of effect on bulk
cells in brain cancers, a low response rate of 10% (all par-498 Cell Stem Cell 1, November 2007 ª2007 Elsevier Inc.tial responses) was observed in a recent phase II study of
Bevacizumab for metastatic renal cancer; however, the
PFS was more than double that of the placebo control
arm (Yang et al., 2003), in keeping with specific activity
against a CSC population. Going forward, novel phase II
study designs more suitable for evaluating the anti-CSC
activity of candidate agents will need to be employed.
For example, a recently proposed randomized discontin-
uation design uses as its major endpoint time to progres-
sion in a subgroup of treated patients with stable disease,
randomized to either continuing therapy or placebo (Ros-
ner et al., 2002). For many years, the impetus for new
study designs has come from investigators working on
antiangiogenesis therapies, which are regarded as cyto-
static rather than cytotoxic and thus may exhibit little evi-
dence of activity in traditional phase I/II testing. The recent
characterization of CSCs in many human cancers now
provides a biologic rationale for these approaches and
underscores the importance of extending such designs
to the clinical evaluation of new anticancer therapies.
Direct Assessment of Anti-CSC Efficacy—An
Attainable Goal?
As tumor shrinkage may not provide an accurate measure
of the effectiveness of CSC-targeted therapies, alternative
surrogate endpoints are required to evaluate whether or
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Recently, significant advances have been made in the field
of molecular imaging, broadly defined as noninvasive
in vivo characterization and measurement of biological
processes at the cellular and molecular level. In a major
step toward direct clinical evaluation of a drug at its mo-
lecular target, a recent report (Smith-Jones et al., 2004)
describes quantitative imaging of the receptor HER2, a
member of the epidermal growth factor receptor family
whose expression is altered in a variety of tumor types,
through the use of gamma and positron emitters chelated
to the anti-HER2 antibody Herceptin. Downregulation of
HER2 was used as a surrogate marker of inhibition of
Hsp90 function by the antitumor agent 17-AAG in an ani-
mal model of breast cancer. This proof-of-principle study
demonstrated that in contrast to imaging methods that
provide anatomic measures of tumor response, direct
quantitative in vivo molecular imaging of the pharmacody-
namics of a targeted agent may allow very rapid assess-
ment of antitumor efficacy. In the future, this technique
could be adapted to image the effects of any agents that
induce altered expression of a target with an extracellular
domain.
Before novel molecular imaging approaches can be
considered for assessment of anti-CSC therapies, how-
ever, relevant surrogate markers must be identified and
validated. To do so will require a full understanding of
the underlying oncogenic pathways that mediate CSC
survival and that likely differ from those that are operative
in bulk tumor cells. In AML, both the NF-kB (Guzman
et al., 2001) and PTEN (Yilmaz et al., 2006) pathways have
been shown to be differentially required for survival by
leukemic and normal hematopoietic stem cells. However,
pathways that are uniquely required by CSCs, but not bulk
tumor cells, have yet to be identified. In the absence of
such CSC-specific markers, new imaging technologies
designed to evaluate whether candidate drugs have
reached their target(s) will need to be combined with
methods to define the relevant cell populations. In this con-
text, it will be necessary to distinguish CSCs not only from
surrounding bulk cancer cells but also from normal tissue
stem cells.
Unfortunately, current characterization of CSC pheno-
type is not precise enough to permit real-time tracking of
CSCs in vivo. Such capability will depend on identification
and validation of additional CSC-specific markers. Avail-
able protocols for isolating CSC-containing cell fractions
generally employ between one and three cell surface
markers, in some cases in addition to depletion of cells
expressing lineage-associated antigens. However, even
when combinations of markers are used, current strate-
gies for purification do not yield functionally homogeneous
populations. For example, in colon cancers, CSCs are en-
riched in the CD133+ cell fraction, but only 1 out of 252
CD133+ colon cancer cells is a CSC as assessed by limit-
ing dilution assays (O’Brien et al., 2007). Similarly, the fre-
quency of leukemia stem cells within the CD34+CD38
fraction in AML ranges from 1 in 104 to 1 in 5 3 106 cells
(Bonnet and Dick, 1997). No precise frequency data areavailable for other tumors in which CSCs have been char-
acterized, but, based on the number of transplanted cells
required for tumor generation in xenotransplant recipients,
the same principle holds true for these cancers as well.
Thus, simply correlating therapeutic effectiveness with re-
duction of a phenotypically defined cell population is
problematic, as there is no assurance that the CSCs
have been eliminated. Further refinement of CSC pheno-
typic characterization will be a difficult task that, based
on experience in the hematopoietic system, may require
combinations of multiple cell surface markers and/or func-
tional parameters.
Detection of CSCs in solid tumors poses additional
challenges relative to hematologic malignancies, given
that cancerous cells in blood or bone marrow are more
readily accessible. For solid tumors, imaging CSCs
in vivo would be preferred over performing tumor biopsies
due to the inherent procedural risks and sampling error of
the latter. In this respect, the field of nanotechnology holds
significant potential (Ferrari, 2005). Modalities such as
magnetic resonance (MR) imaging are constrained by rel-
ative insensitivity to low concentrations of imaging agent,
which is problematic for detection of rare cell populations.
The physical properties of nanoparticles enable this limita-
tion to be circumvented by coupling each targeted particle
with large payloads of the imaging agent. A recent report
describes MR detection of tumors as small as 50 mg
in vivo through the use of magnetic nanoparticles conju-
gated with Herceptin (Lee et al., 2007), demonstrating
the high sensitivity of such systems, albeit still far from
the ideal of single cell visualization. With improved sensi-
tivity, imaging of CSCs in patients undergoing treatment
might one day be possible using engineered nanoparticles
targeted to CSC-specific markers. However, the success
of such an approach would be predicated on the ability to
simultaneously and uniquely image multiple targeted
agents bound in the same location, as single markers to
identify CSC populations will likely be insufficient.
Evaluation of CSC Eradication
Following Treatment
Minimal residual disease (MRD) is defined as the presence
of residual malignant cells at a level that is not detectable
by routine means in patients achieving clinical remission,
usually on the order of 0.1%–0.01%. The goal of MRD
evaluation is to guide therapeutic decisions by distin-
guishing patients who do or do not require additional ther-
apy to prevent relapse; in this context, it is important to
determine specifically whether or not residual CSCs re-
main. The presence of MRD in sites such as lymph nodes
or bone marrow is commonly assessed using polymerase
chain reaction or other methods to detect cancer-specific
molecular markers such as chromosomal translocations.
However, these approaches do not differentiate persisting
CSCs, which may cause relapse, from residual cancer
cells that do not have tumor-initiating activity. The use of
flow cytometry to detect residual CSCs is also compli-
cated by similarities in the phenotype of CSCs and normal
tissue stem cells. Some tumor stem cell markers haveCell Stem Cell 1, November 2007 ª2007 Elsevier Inc. 499
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counterparts, for example CD123 on leukemia stem cells
in AML (Jordan et al., 2000). However, in many cases there
is significant overlap between the expression pattern of
CSC-containing cell fractions and that of normal stem
cells. For example, CD133, a marker of CSCs in colon
and brain cancers, has also been used to enrich both nor-
mal human hematopoietic stem cells and stem cells in the
central nervous system. In the absence of CSC-unique
markers, evaluation of clinically relevant MRD would be
greatly aided by other strategies to distinguish CSCs from
both bulk tumor cells and normal stem cells. CSCs likely
have a gene signature that differs from that of nontumori-
genic cancer cells. For example, transformation of murine
committed hematopoietic progenitors by expression of
an MLL oncogene results in reactivation of self-renewal
genes not normally expressed by these cells (Krivtsov
et al., 2006). However, a self-renewal signature in leuke-
mic stem cells may be difficult to distinguish from that of
normal hematopoietic stem cells. Furthermore, with exist-
ing microarray-based global gene or microRNA profiling
technology, it is impossible to distinguish expression
levels contributed by rare cells from background variabil-
ity. Thus, this sort of approach would first require isolation
of a cell population significantly enriched for CSCs, which
is currently not feasible. In the future, the ability to detect
residual CSCs in patients following therapy will require
substantial advances in both gene expression analysis
and/or CSC purification strategies.
The Importance of Preclinical Development
In view of the difficulties faced in assessment of clinical ef-
ficacy of CSC-targeted agents, and therefore in prioritiza-
tion of drug entry into the later stages of clinical develop-
ment, more attention must be paid to the methods used
in screening and preclinical testing in order to maximize
return on the considerable time and resources invested
in long-term trials. Drug discovery platforms commonly
employ tumor cell lines to screen for drugs with antitumor
activity. A major drawback of this approach is that drugs
demonstrating activity against bulk tumor cells or cell lines
may not have activity against CSCs. Where possible, cells
from primary patient samples enriched for CSC popula-
tions should be used for testing or validation. Screening
strategies must focus on compounds that attenuate
self-renewal or other key traits of CSCs. Ideally, these
properties should be assayed in vivo, generally by xeno-
transplantation, but this is impractical for large-scale,
high-throughput screening, necessitating the use of surro-
gate in vitro assays such as neurosphere cultures for brain
CSCs. A recent chemical screen for inhibitors of mouse
neurosphere proliferation, a property highly associated
with self-renewal, identified 160 compounds, including
some that inhibited proliferation of cultures enriched for
human brain CSCs (Diamandis et al., 2007), demonstrat-
ing the feasibility of such an approach. Furthermore, novel
techniques such as fluorescent cell barcoding (Krutzik and
Nolan, 2006) will enable rapid screening for compounds
that induce differentiation in addition to those that affect500 Cell Stem Cell 1, November 2007 ª2007 Elsevier Inc.proliferation and/or cell death. Another powerful tool for
drug developers is the recently published Connectivity
Map, a collection of gene expression profiles of cultured
human cells treated with 164 distinct bioactive small mol-
ecules (Lamb et al., 2006). This chemical genomic library
could be queried for agents that attenuate a stem cell
gene signature or induce a differentiated state. The map
could also be used to identify compounds that mimic or
complement the activity of known anti-CSC agents.
Ultimately, CSCs are defined by their capacity to gener-
ate tumors in vivo. In vivo assays allow functional assess-
ment of characteristics of primitive cells that cannot be
fully realized under in vitro conditions. Thus, any com-
pounds identified and tested using in vitro assays should
ideally be validated in vivo before proceeding to the clinic.
Examples of agents that have shown activity against
CSCs in human xenograft models include the NF-kB in-
hibitor parthenolide (Guzman et al., 2005) and the anti-
CD44 monoclonal antibody H90 (Jin et al., 2006) in AML;
and Bevacizumab (Calabrese et al., 2007) and bone mor-
phogenic proteins (Piccirillo et al., 2006) in brain tumors.
Whether activity against CSCs assayed in xenograft
models will translate into survival benefits in patients has
yet to be determined in long-term clinical trials, but there
is some correlation, at least in AML, between engraftment
ability of CSCs in xenograft recipients and disease prog-
nosis (Pearce et al., 2006). Demonstration that the results
of drug testing in experimental xenograft models are able
to predict treatment outcomes in clinical trials would put
a very powerful tool in the hands of drug developers.
Unfortunately, in vivo functional assays do not exist for
most types of human cancer. In addition, current xeno-
graft models, in particular those for human solid tumors,
do not fully emulate all disease settings. Progress in devel-
oping and optimizing human cancer models has been im-
peded in part by a lack of understanding of the microenvi-
ronmental requirements of CSCs, including both humoral
and cellular factors. In the absence of human cancer
models, preclinical in vivo testing of anticancer agents has
been done using murine models. However, mouse models
do not always recapitulate human disease. As well, there
are important species-specific differences in underlying
oncogenic pathways. Thus, despite the complexities and
inherent limitations of modeling human cancer in in vivo
systems, this is a vital avenue of research not only for pre-
clinical drug development, but also for characterization
of CSC populations and identification of surrogate bio-
marker endpoints of clinical drug efficacy.
Evaluation of Toxicity to Normal Stem Cells
CSCs and normal stem cells share many properties, which
may make it difficult to devise therapies that both target
CSCs and spare their normal counterparts. Thus, in paral-
lel with development of new methodologies to assess
eradication of CSCs, attention must be paid to proper
evaluation of toxicity to normal tissue stem cells. In pre-
clinical animal testing and short-term phase I/II clinical
trials, toxicity at the level of mature and progenitor cells
is assessed using indicators such as hematopoietic
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of short-term toxicity would not necessarily preclude tox-
icity to normal stem cells as evidenced by effects on tissue
maintenance over longer periods of time. Thus, surrogate
measures of stem cell toxicity during preclinical testing
would be of great value when trying to prioritize drugs
with anti-CSC activity for clinical development. In the
hematopoietic system, xenotransplant systems are avail-
able in which the potential of normal stem cells for self-
renewal, multilineage differentiation, and proliferation can
be assessed in vivo. Using such a system, Guzman et al.
demonstrated that parthenolide treatment inhibits the
repopulation ability of primitive AML cells while sparing
normal engrafting cells (Guzman et al., 2005). A similar
approach could be used to evaluate the toxicity of other
agents such as rapamycin that also target CSC-specific
survival pathways in leukemia (Yilmaz et al., 2006). How-
ever, assays for normal human stem/progenitor cells from
nonhematopoietic tissues are lacking, with the exception
of neurosphere assays in the central nervous system.
Future research into the hierarchical structure of normal
tissues and the development of surrogate stem cell as-
says will greatly aid clinical assessment of toxicity of
candidate agents designed to eradicate CSCs.
Conclusion
The mounting evidence that the growth of many types of
human cancer is driven by biologically distinct CSCs dic-
tates a reexamination of how anticancer therapies are de-
veloped and evaluated. There is a clear need for agents
that target these cancer-sustaining cells. However, cur-
rent methods used to assess the efficacy of anticancer
therapies are not likely to predict activity against CSCs,
necessitating the development of new strategies for
both preclinical and clinical evaluation. Given the current
state of technology, direct clinical assessment of CSC
eradication is a still distant goal. The major obstacles are
identification of new markers that will enable tracking of
CSCs within the bulk tumor or on a background of normal
cells following therapy, characterization and validation of
surrogate endpoints of drug efficacy, and improved reso-
lution of molecular imaging techniques. For the present,
there should be a greater emphasis on careful selection
of candidate agents during preclinical development using
novel drug discovery platforms and functional validation
of activity in in vivo models. Parallel efforts to develop
and improve xenograft models of human cancer are also
required. Once these challenges are addressed, the devel-
opment of effective CSC-targeted therapies may be within
reach.
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